A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction

Journal of Cardiac Failure

Volumn 17, Issue 12, 2011, Pages 973-981

  Udelson, James E ^a   Bilsker, Martin ^b   Hauptman, Paul J ^c   Sequeira, Rafael ^b   Thomas, Ignatius ^d   O'Brien, Terrence ^e   Zimmer, Christopher ^f   Orlandi, Cesare ^f   Konstam, Marvin A ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b JACKSON MEMORIAL HOSPITAL   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Medical Research Institute   (United States)

^e RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^f OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

diuretics; Heart failure; vasopressin

Indexed keywords

FUROSEMIDE; PLACEBO; TOLVAPTAN;

ADULT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART FAILURE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MICTURITION DISORDER; MONOTHERAPY; MULTICENTER STUDY; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SODIUM BLOOD LEVEL; SODIUM RESTRICTION; SYSTOLIC DYSFUNCTION; THIRST; URINE VOLUME;

BENZAZEPINES; BODY WEIGHT; DIURETICS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FUROSEMIDE; HEART FAILURE, SYSTOLIC; HUMANS; MALE; MIDDLE AGED; RECEPTORS, VASOPRESSIN; STATISTICS AS TOPIC; STROKE VOLUME; VASOPRESSINS; VENTRICULAR FUNCTION, LEFT;

EID: 84855950434     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2011.08.005     Document Type: Article

References (32)

1. E.W. Schrier, and R.G. Fassett Pathogenesis of sodium and water retention in cardiac failure Renal Failure 20 1998 773 781 (Pubitemid 28541344)
2. B.F. Palmer Potassium disturbances associated with the use of diuretics D. Seldin, G. Giebisch, Diuretic Agents - Clinical Physiology and Pharmacology 1997 Academic Press Inc San Diego, Calif 571 583
3. R.R. Ghose, and S.K. Gupta Synergistic actions of metolazone with loop diuretics Br Med J 812 1981 1432 1433 (Pubitemid 11096245)
4. J.E. Udelson, W.B. Smith, G.H. Hendrix, C.A. Painchaud, M. Ghazzi, and I. Thomas Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure Circulation 104 2001 2417 2423 (Pubitemid 33108374)
5. M. Gheorghiade, I. Niazi, J. Ouyang, F. Czerwiec, J. Kambayashi Orlandi C for the tolvaptan Investigators Vasopressin receptor blockade in patients with congestive heart failure: results from a randomized, double-blind study Circulation 107 2003 2690 2696 (Pubitemid 36667242)
6. M. Gheorghiade, W.A. Gattis, C.M. O'Connor, K.F. Adams, U. Elkayam, and A. Barbagelata Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial JAMA 291 2004 1963 1971 (Pubitemid 38544277)
7. 2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats J Pharmacol Exp Ther 287 1998 860 867 (Pubitemid 29131593)
8. M.A. Konstam, M. Gheorghiade, J.C. Burnett Jr., L. Grinfeld, A.P. Maggioni, and K. Swedberg Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial JAMA 297 2007 1319 1331 (Pubitemid 46513233)
9. S.R. Goldsmith Vasopressin: a therapeutic target in congestive heart failure? J Card Fail 5 1999 347 356 (Pubitemid 30033676)
10. 2- vasopressinergic receptors Am J Physiol 255 1988 H261 H265
11. R.W. Schrier, T. Berl, and R.J. Anderson Osmotic and nonosmotic control of vasopressin release Am J Physiol 236 1979 F321 F332
12. Y.J. Xu, and V. Gopalakrishnan Vasopressin increases cytosolic free calcium in neonatal rat cardiocyte: evidence for V1 receptor subtype Circ Res 69 1991 239 245
13. A. Tahara, Y. Tomura, K. Wada, T. Kusayama, J. Tsukada, and N. Ishii Effects of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte Cardiovasc Res 38 1998 198 205 (Pubitemid 28275630)
14. J. Fukuzawa, T. Haneda, and K. Kikuchi Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor Mol Cell Biochem 195 1999 93 98 (Pubitemid 29259773)
15. G.A.J. Riegger, G. Liebau, and K. Kochsiek Antidiuretic hormone in congestive heart failure Am J Med 72 1982 49 52 (Pubitemid 12090785)
16. Y. Yamane Plasma ADH level in patients with chronic congestive heart failure Jpn Circ J 32 1968 745 759
17. S.R. Goldsmith, G.S. Francis, A.W. Cowley, T.B. Levine, and J.N. Cohn Increased plasma arginine vasopressin levels in patients with congestive heart failure J Am Coll Cardiol 1 1983 1385 1390 (Pubitemid 13054124)
18. G.S. Francis, C. Benedict, and D.E. Johnstone Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: A substudy of the Studies of Left Ventricular Dysfunction Circulation 82 1990 1724 1729 (Pubitemid 20367975)
19. M.A. Creager, D.P. Faxon, S.S. Cutler, O. Kohlmann, T.J. Ryan, and H. Gavras Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: Comparison with the renin-angiotensin system and the sympathetic nervous system J Am Coll Cardiol 7 1986 758 765 (Pubitemid 16107118)
20. J.-L. Rouleau, M. Packer, and L. Moye Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril J Am Coll Cardiol 24 1994 583 591 (Pubitemid 24295729)
21. M. Gheorghiade, M.A. Konstam, J.C. Burnett Jr., L. Grinfeld, A.P. Maggioni, and K. Swedberg Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials JAMA 297 2007 1332 1343 (Pubitemid 46513234)
22. G.L. Neuberg, A.B. Miller, and C.M. O'Connor Diuretic resistance predicts mortality in patients with advanced heart failure Am Heart J 144 2002 31 38 (Pubitemid 34734752)
23. M. Domanski, J. Norman, B. Pitt, M. Haigney, S. Hanlon, and E. Peyster Diuretic use, progressive heart failure, and death in patients in the Studies of Left Ventricular Dysfunction (SOLVD) J Am Coll Cardiol 42 2003 705 708 (Pubitemid 37000189)
24. 1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy Circulation 105 2002 1348 1353 (Pubitemid 34260427)
25. H.L. Hillege, A.R.J. Girbes, and P.J. de Kam Renal function, neurohormonal activation and survival in patients with chronic heart failure Circulation 102 2000 203 210 (Pubitemid 30451778)
26. H.M. Krumholz, Y.T. Chen, and V. Vaccarino Correlates and impact on outcome of worsening renal function in patients 65 years of age with heart failure Am J Cardiol 85 2000 1110 1113 (Pubitemid 30214258)
27. L.C. Costello-Boerrigter, W.B. Smith, G. Boerrigter, J. Ouyang, C.A. Zimmer, and C. Orlandi Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure Am J Physiol Renal Physiol 290 2006 F273 F278
28. W.C. Grinstead Discontinuation of chronic diuretic therapy in stable congestive heart failure secondary to coronary artery disease or to idiopathic dilated cardiomyopathy Am J Cardiol 73 1994 881 886 (Pubitemid 24158309)
29. M.D. Guazzi, P.G. Agostoni, and G.B. Perego The apparent paradox of neurohormonal axis inhibition after body fluid volume depletion in patients with chronic congestive heart failure and water retention Br Heart J 72 1994 534 539 (Pubitemid 24375746)
30. G.C. Marenzi, G. Lauri, and M. Grazi Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure J Am Coll Cardiol 38 2001 963 968 (Pubitemid 32912695)
31. D.C. Merrill, and A.W. Cowley Jr. Chronic effects of vasopressin on plasma renin activity in sodium-restricted dogs Am J Physiol 250 1986 F460 F469
32. C.A. Ecelbarger, G.H. Kim, S. Masilamani, C. Mitchell, I. Reyes, and J.G. Verbalis Vasopressin-mediated regulation of epithelial sodium channel abundance in rat kidney Am J Physiol 279 2000 F46 F53